Grospisk en es it fr

Grospisk Brand names, Grospisk Analogs

Grospisk Brand Names Mixture

  • No information avaliable

Grospisk Chemical_Formula


Grospisk RX_link

Grospisk fda sheet

Grospisk FDA

Grospisk msds (material safety sheet)

Grospisk MSDS

Grospisk Synthesis Reference

No information avaliable

Grospisk Molecular Weight

1270.28 g/mol

Grospisk Melting Point

No information avaliable

Grospisk H2O Solubility

Freely soluble as sodium salt (> 200mg/mL)

Grospisk State


Grospisk LogP

No information avaliable

Grospisk Dosage Forms

Powder for solution (for injection)

Grospisk Indication

For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Grospisk Pharmacology

Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.

Grospisk Absorption

No information avaliable

Grospisk side effects and Toxicity

Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.

Grospisk Patient Information

No information avaliable

Grospisk Organisms Affected

Aspergillis, Candida and other fungi